The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed, and funded by an Alkermes company.
Showing 10 of 103 results
Sort by date:
Descending
Jun 2017
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
CNS Drugs
AUTHOR(S)
May 2017
Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
Journal of Clinical Psychopharmacology
AUTHOR(S)
Apr 2017
Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
Journal of Addiction Medicine
AUTHOR(S)
Apr 2017
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine
American Journal of Psychiatry
AUTHOR(S)
Jan 2017
Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia
Schizophrenia Research
AUTHOR(S)
Nov 2016
Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)
Mar 2016
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia
International Clinical Psychopharmacology
AUTHOR(S)
Aug 2015
A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)
Apr 2015
Treating opioid dependence with injectable extended-release naltrexone (XR-NTX) who will respond?
Journal of Addiction Medicine
AUTHOR(S)
Nov 2013
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
Patient Preference and Adherence
AUTHOR(S)
